Global Drug Eluting Coronary Stent System Market Growth 2026-2032
Description
The global Drug Eluting Coronary Stent System market size is predicted to grow from US$ 6057 million in 2025 to US$ 8146 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.
The drug-eluting coronary stent system is a medical device used to treat coronary artery disease. It slowly releases drugs by coating the stent surface with a drug coating to inhibit intimal hyperplasia and reduce the occurrence of restenosis. Compared with bare metal stents, drug-eluting coronary stents have lower restenosis rates and better long-term effects.
United States market for Drug Eluting Coronary Stent System is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Drug Eluting Coronary Stent System is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Drug Eluting Coronary Stent System is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Drug Eluting Coronary Stent System players cover Boston Scientific, Medtronic, Abbott, B.Braun, BD, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Drug Eluting Coronary Stent System Industry Forecast” looks at past sales and reviews total world Drug Eluting Coronary Stent System sales in 2025, providing a comprehensive analysis by region and market sector of projected Drug Eluting Coronary Stent System sales for 2026 through 2032. With Drug Eluting Coronary Stent System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug Eluting Coronary Stent System industry.
This Insight Report provides a comprehensive analysis of the global Drug Eluting Coronary Stent System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drug Eluting Coronary Stent System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drug Eluting Coronary Stent System market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug Eluting Coronary Stent System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug Eluting Coronary Stent System.
This report presents a comprehensive overview, market shares, and growth opportunities of Drug Eluting Coronary Stent System market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Rapamycin Eluting Stent
Everolimus Eluting Stent
Others
Segmentation by Application:
Hospitals
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Boston Scientific
Medtronic
Abbott
B.Braun
BD
Biotronik AG
Stentys SA
Sino Medical
Beijing ESSEN Technology
Beijing Advanced Medical Technologies
LifeTech Scientific Corporation
MicroPort Scientific Corporation
Yilson Medical Technology
Lepu Medical Technology
Shandong Hua'an Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Drug Eluting Coronary Stent System market?
What factors are driving Drug Eluting Coronary Stent System market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Drug Eluting Coronary Stent System market opportunities vary by end market size?
How does Drug Eluting Coronary Stent System break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The drug-eluting coronary stent system is a medical device used to treat coronary artery disease. It slowly releases drugs by coating the stent surface with a drug coating to inhibit intimal hyperplasia and reduce the occurrence of restenosis. Compared with bare metal stents, drug-eluting coronary stents have lower restenosis rates and better long-term effects.
United States market for Drug Eluting Coronary Stent System is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Drug Eluting Coronary Stent System is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Drug Eluting Coronary Stent System is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Drug Eluting Coronary Stent System players cover Boston Scientific, Medtronic, Abbott, B.Braun, BD, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Drug Eluting Coronary Stent System Industry Forecast” looks at past sales and reviews total world Drug Eluting Coronary Stent System sales in 2025, providing a comprehensive analysis by region and market sector of projected Drug Eluting Coronary Stent System sales for 2026 through 2032. With Drug Eluting Coronary Stent System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug Eluting Coronary Stent System industry.
This Insight Report provides a comprehensive analysis of the global Drug Eluting Coronary Stent System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drug Eluting Coronary Stent System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drug Eluting Coronary Stent System market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug Eluting Coronary Stent System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug Eluting Coronary Stent System.
This report presents a comprehensive overview, market shares, and growth opportunities of Drug Eluting Coronary Stent System market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Rapamycin Eluting Stent
Everolimus Eluting Stent
Others
Segmentation by Application:
Hospitals
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Boston Scientific
Medtronic
Abbott
B.Braun
BD
Biotronik AG
Stentys SA
Sino Medical
Beijing ESSEN Technology
Beijing Advanced Medical Technologies
LifeTech Scientific Corporation
MicroPort Scientific Corporation
Yilson Medical Technology
Lepu Medical Technology
Shandong Hua'an Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Drug Eluting Coronary Stent System market?
What factors are driving Drug Eluting Coronary Stent System market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Drug Eluting Coronary Stent System market opportunities vary by end market size?
How does Drug Eluting Coronary Stent System break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
109 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Drug Eluting Coronary Stent System by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Drug Eluting Coronary Stent System by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
